PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs

Reportbuyer.com just published a new market research report: PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

London (PRWEB) November 20, 2013

PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs

Summary

The CRO Benchmark Report applies GlobalData’s proprietary ranking methodology to compare the competitive positions of 11 leading CRO companies on 17 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders. Throughout the report, GlobalData’s Industry Dynamics Team provides you with expert insight, expanding on each of the metrics discussed. In addition to the financial metrics, this report discusses trends impacting the CRO marketplace, along with partnering and acquisition activity, and operations strategy. This report also provides drill-down analyses of three service lines and four geographies examining each of these segment’s revenue and growth leaders, and business development strategies. Lastly, this report provides GlobalData’s outlook on the CRO sector and each company’s future competitive position.

Highlights

About the Report

The CRO market is highly fragmented comprised of some 1,000 individual companies, most of which are privately owned. These companies vary significantly in size and breadth of services – from a four person bioanalysis research lab in Thailand to companies like Quintiles and Covance which have tens of thousands of employees in over 100 countries across the globe. GlobalData identified 11 CROs to apply its benchmarking methodology providing a foundation for strategic discussion and analysis. GlobalData’s coverage examines these CROs from a unique company-centric lens – combining financial performance and resources allocation with partnering activity and regional developments to assess a company’s overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies corporate growth. We also covered some 30 other privately-held CROs to give our analysis more specificity and granularity.

Key Questions Answered

-What specific strategies are these CROs employing to gain market share?
-What drivers accounted for the revenue growth for the company over the past year?
-Which trends will affect the CRO marketplace over the next few years?
-What particular services or capabilities are my competitors developing?
-Who are the revenue and growth leaders in each service line and geography?
-What specific business development activities are taking place, in terms of partnerships or M&A?
-How are CROs growing their physical infrastructures and human resources to better serve the needs of their customers?
-What region-specific operations and capabilities are CROs adding to gain share in emerging markets?

Scope

-Analysis of the key drivers and trends shaping the global CRO market; including biologics manufacturing, emerging markets, and eClinical technologies
-A deep dive into the synergies behind partnering and acquisition activity
-Discussion of business line and regional segment strategies
-Assessments of company financials by revenue, margin, expense and capital structure
-Firm utilization, resources management, and efficiency metrics
-Leadership/management changes

Reasons to buy

-Analyze and track the strategies that these CROs are using to gain share in the increasingly competitive market
-Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure
-Organize your sales and marketing strategy to identify companies with proprietary technologies to maximize opportunities for strategic investment or partnerships
-Use this information as an independent source for your due diligence and transaction strategy

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 14
1.2 List of Figures 14
2 Introduction 17
2.1 Report Scope 17
2.1.1 GlobalData Selection Criteria 18
2.1.2 Companies Financially Benchmarked 18
2.1.3 Other Companies Covered 18
2.2 Upcoming Reports 19
2.3 Recently Published Reports 19
2.4 GlobalData’s Benchmarking Methodology 20
2.5 GlobalData CRO Benchmark Leader: EPS Corporation 20
3 CRO Market Dynamics 22
3.1 Outsourcing Service Delivery Models 22
3.1.1 Fully Integrated Service Model 22
3.1.2 Functional Service Model 23
3.1.3 The Bottom Line: Use a Hybrid Approach 24
3.2 Quintiles Goes Public 24
3.2.1 Quintiles IPO Raises $947M, Pricing an Increased Number of Shares at Top Range 24
3.3 Weak Demand for Preclinical Services Causes CROs to Economize 25
3.4 CROs Are Transitioning into Becoming Experts in Biologics Manufacturing 26
3.4.1 WuXi Will Become a Leader in Biologics Manufacturing through its Multi-pronged Strategy 27
3.4.2 Catalent Opens New Manufacturing Center for Biologic Drug Development 29
3.4.3 ShangPharma Inks Two mAb Partnerships 30
3.5 Emerging Locations in Asia Will See the Greatest Investment and Growth 31
3.5.1 Location, Location – Footprint Growth Has Become More Important than Cost Reduction 31
3.5.2 Will Concerns about Patient Safety Bring Down the Indian Clinical Trial Market? 33
3.6 eClinical Technologies Will be Key Drivers to Accelerating Time-to-Market 35
3.6.1 Icon and Cerner Team Up to Streamline Late-Phase Studies 35
3.6.2 Parexel Introduces MyTrials Platform 36
3.6.3 INC Research Expands Partnership with Medidata Solutions 37
3.6.4 Quintiles Unveils its Next-Generation Infosario Analytics Platform 37
3.6.5 Covance Launches Xcellerate to Increase Clinical Trial Optimization 38
4 Collaboration and Acquisition Strategies 39
4.1 Overview 39
4.2 M&A Analysis 43
4.2.1 KKR Makes a Splash into CRO Biz with PRA Buy 43
4.2.2 Quintiles Invests in Personalized Medicine 44
4.2.3 Patheon Completes Purchase of Banner Pharmacaps 44
4.2.4 Clinipace Doubles in Size with Paragon Buyout 45
4.2.5 Accenture Complements its R&D Service Offerings with Acquisition of Octagon 45
4.2.6 Catalent Pharma Buys Aptuit’s CTS Business 46
4.2.7 Charles River and Covance Expand Microbial Identification Capabilities 46
4.3 Strategic Partnerships with Large Pharmaceutical Clients 47
4.3.1 Quintiles and Merck Serono Announce Innovative Clinical Development Partnership 47
4.3.2 Charles River and AstraZeneca Align to Accelerate Drug Development 48
4.3.3 Covance Deals 48
4.3.4 Pfizer Improves Clinical Trial Flexibility with Icon and Parexel Partnership 49
4.3.5 Aptuit and GSK Extend Strategic Alliance 49
4.3.6 INC Research Enters into FSP Collaboration with Astellas 50
4.3.7 PRA Announces Strategic Biosimilar Development Agreement with Amgen 50
4.3.8 Parexel and Catalent Combine Core Competencies to Streamline Supply Chain 51
5 Financial Management 52
5.1 CRO Market Competitive Landscape Assessment 53
5.1.1 As Quintiles Goes, So Goes the CRO Market 53
5.2 Financial Management: Heat Map 55
5.2.1 Quintiles Was the Financial Management Leader in 2012 55
5.3 Financial Performance Metrics 56
5.3.1 Revenue 56
5.3.2 Revenue Growth YtY 58
5.3.3 Operating Income 60
5.3.4 Operating Income Growth YtY 61
5.3.5 Operating Margin 63
6 Expense Management 65
6.1 CRO Market Competitive Landscape Assessment 65
6.1.1 Cost Containment Remains a Strategic Driver for CROs 65
6.2 Expense Management: Heat Map 67
6.2.1 CMIC Was the Expense Management Leader in 2012 67
6.3 Expense Performance Metrics 68
6.3.1 S,G&A Expense 68
6.3.2 G&A Expense as a Percentage of Revenue 70
6.3.3 S&M Expense as a Percentage of Revenue 71
6.3.4 Total OpEx as a Percentage of Revenue 72
7 Services Analysis 74
7.1 Overview 74
7.2 Clinical Laboratory Services Landscape Assessment 76
7.2.1 Demand for Clinical Lab Services is Fueling Overall Market Growth 76
7.2.2 Expand Delivery of Clinical Laboratory Services 78
7.2.3 Quintiles Forms New Biomarker Research and Development Company 79
7.3 Revenue and Growth Leaders 80
7.3.1 Revenue 80
7.3.2 Revenue Growth YtY 82
7.4 Manufacturing Services Landscape Assessment 83
7.4.1 Catalent Solidifies its Position as a Leading Provider of CMO Services 83
7.4.2 Aptuit Launches New Approach to CMC 85
7.4.3 API Supply Agreements 85
7.5 Revenue and Growth Leaders 86
7.5.1 Revenue 86
7.5.2 Revenue Growth YtY 88
7.6 Advisory and Support Services Landscape Assessment 89
7.6.1 Catalent’s Acquisition of Aptuit’s CTS Business Drove Advisory Revenues in 2012 89
7.6.2 Strategic Advisory Services 91
7.6.3 Staffing and Customer Support Services 92
7.7 Revenue and Growth Leaders 94
7.7.1 Revenue 94
7.7.2 Revenue Growth YtY 96
8 Regional Analysis 98
8.1 Overview 98
8.2 North America Landscape Assessment 101
8.2.1 Pharma’s Large Revenue Base in North America Continues to Drive CRO Sector Growth 101
8.3 Regional Developments 103
8.3.1 Covance Collaborates with M2Gen and BioPontis Alliance 103
8.3.2 AMRI Signs Agreement to License its Novel Tubulin Inhibitor Program to Chai Therapeutics 104
8.3.3 Ockham Completes Acquisition of Nexus Oncology 105
8.3.4 Synteract and HCR Combine to Form Multinational CRO 105
8.3.5 Accelovance Buys Radiant’s CRO Division 105
8.3.6 Frontage Inks Deal with AtheroNova 106
8.3.7 Pharm-Olam Completes Phase III Ophthalmology Study for InSite Vision 106
8.4 Revenue and Growth Leaders 107
8.4.1 Revenue 107
8.4.2 Revenue Growth YtY 109
8.5 Europe Landscape Assessment 110
8.5.1 European CRO Market Witnessed a Significant Pullback in Growth 110
8.6 Regional Developments 112
8.6.1 TFS International Acquires Italian CRO Dimensione Ricerca 112
8.6.2 Quintiles Signs Deal to Bring Almirall’s LAMA Therapy to the UK 112
8.6.3 Icon Selected by European Pharma Companies as a Global Strategic Partner 113
8.6.4 CromSource Adds Early-Phase Research Unit in Partnership with CRC 113
8.6.5 Covance Inks Tech Transfer Deal with France’s Inserm Transfert SA 114
8.7 Revenue and Growth Leaders 114
8.7.1 Revenue 114
8.7.2 Revenue Growth YtY 116
8.8 Asia-Pacific Landscape Assessment 118
8.8.1 APAC Market Remains Hot for Clinical Outsourcing 118
8.9 Regional Developments 121
8.9.1 Japanese CROs Grow their Domestic Footprints 121
8.9.2 AMRI Drives SmartSourcing Strategy in Japan 121
8.9.3 Covance-BML Boost Clinical Trial Lab in Japan 122
8.9.4 Frontage Hired by Local Chinese Clients to Develop Drugs Overseas 122
8.10 Revenue and Growth Leaders 123
8.10.1 Revenue 123
8.10.2 Revenue Growth YtY 124
8.11 Emerging Markets Landscape Assessment 126
8.11.1 BRICs and Other Emerging Regions Still Represent Huge Untapped Markets for R&D 126
8.12 Regional Developments 128
8.12.1 Central and Latin America 128
8.12.2 Emerging EMEA 129
8.12.3 China 132
8.12.4 India 133
8.12.5 Rest of Asia 135
8.13 Revenue and Growth Leaders 137
8.13.1 Revenue 137
8.13.2 Revenue Growth YtY 139
9 Resource Management Strategies 141
9.1 Overview 142
9.2 Operations and Global Service Delivery 143
9.2.1 Expand Strategic Investment in Emerging Markets to Support Business Growth 143
9.2.2 PPD and Icon Grow Bioassay Capabilities in the US and Europe 147
9.2.3 EPS Corporation Separates Business Units to Streamline Efficiency 149
9.2.4 AMRI Realigns its Drug Discovery Services 149
9.2.5 Laboratory Accreditations and Certifications 149
9.3 Firm Utilization: Heat Map 151
9.3.1 Covance Was the Firm Utilization Leader in 2012 151
9.4 Firm Utilization Metrics 152
9.4.1 Headcount Growth YtY 152
9.4.2 Revenue per Employee 153
9.4.3 Clinical Services Revenue per Clinical Services Employee 155
9.4.4 G&A Expense per G&A Employee 156
9.4.5 S&M Expense per S&M Employee 157
9.5 Human Capital Leadership Changes 158
9.5.1 Source Therapeutic and Regional Expertise to Boost Clinical Operations 158
9.6 Capital Management: Heat Map 160
9.6.1 EPS Was the Capital Management Leader in 2012 due to its Higher Liquidity 160
9.7 Capital Structure Metrics 161
9.7.1 Debt/Equity Ratio 161
9.7.2 Current Ratio 162
9.7.3 Cash Ratio 163
9.8 Share Offerings and Debt Restructurings 164
9.8.1 Proceeds from Share Repurchases Used to Pay-down Debt and Finance Acquisitions 164
10 Future Outlook 165
10.1 CRO Market 165
10.2 Vendor Positioning 167
11 Appendix 168
11.1 Research Methodology 168
11.1.1 Coverage 168
11.1.2 Secondary Research 168
11.2 About the Author 169
11.2.1 Adam Dion, Industry Analyst 169
11.3 Director, Healthcare Industry Dynamics 170
11.4 Global Head of Healthcare 170
11.5 About the Industry Dynamics Team 170
11.6 About GlobalData 171
11.7 Disclosure Information 171
11.8 Disclaimer 171

1.1 List of Tables

Table 1: GlobalData Benchmark Rankings, Contract Research Organizations, 2012 22
Table 2: Financial Management Composite Scores, 2012 56
Table 3: Expense Management Composite Scores, 2012 68
Table 4: Infrastructure Investments, Emerging Markets, 2012–2013 146
Table 5: Infrastructure Investments, US and Europe, 2012–2013 149
Table 6: Recent Laboratory Accreditations and Certifications, Worldwide, 2012–2013 151
Table 7: Firm Utilization Composite Scores, 2012 152
Table 8: Key Leadership Changes, 2012–2013 159
Table 9: Capital Management Composite Scores, 2012 161
Table 10: Share Offerings and Debt Restructurings, 2012–2013 165

1.2 List of Figures

Figure 1: Contract Research Organization Deals and Deal Values ($m), 2008–2012 41
Figure 2: Number of M&A Deals and Deal Values ($m), 2008–2012 42
Figure 3: Number of Licensing Deals and Deal Values ($m), 2008–2012 43
Figure 4: Leading CRO Landscape Assessment – FY2012 Revenue Growth vs. Operating Margin 55
Figure 5: Revenue ($m) by Company, 2012 58
Figure 6: Revenue Growth by Company, 2012 60
Figure 7: Operating Income ($m) by Company, 2012 61
Figure 8: Operating Income Growth by Company, 2012 63
Figure 9: Operating Margin by Company, 2012 65
Figure 10: Leading CRO Landscape Assessment – FY2012 S,G&A Expense vs. Total OpEx 67
Figure 11: S,G&A Expense ($m) by Company, 2012 69
Figure 12: G&A Expense as a Percentage of Revenue by Company, 2012 71
Figure 13: S&M Expense as a Percentage of Revenue by Company, 2012 72
Figure 14: Total OpEx Spending as a Percentage of Revenue by Company, 2012 73
Figure 15: Combined Peer Group Revenue ($m) by Service Line, 2010–2012 76
Figure 16: Clinical Lab Services Landscape, 2012 78
Figure 17: Clinical Laboratory Services Revenue ($m) by Company, 2012 82
Figure 18: Clinical Laboratory Services Revenue Growth by Company, 2012 83
Figure 19: Manufacturing Services Landscape, 2012 85
Figure 20: Manufacturing Services Revenue ($m) by Company, 2012 88
Figure 21: Manufacturing Services Revenue Growth by Company, 2012 89
Figure 22: Advisory and Support Services Landscape, 2012 91
Figure 23: Advisory and Support Services Revenue ($m) by Company, 2012 96
Figure 24: Advisory and Support Services Revenue Growth by Company, 2012 98
Figure 25: Combined Peer Group Revenue ($m) by Region, 2010–2012 101
Figure 26: North America Landscape Assessment, 2012 103
Figure 27: North America Revenue ($m) by Company, 2012 109
Figure 28: North America Revenue Growth by Company, 2012 110
Figure 29: Europe Landscape Assessment, 2012 112
Figure 30: Europe Revenue ($m) by Company, 2012 116
Figure 31: Europe Revenue Growth by Company, 2012 117
Figure 32: APAC Landscape Assessment, 2012 121
Figure 33: APAC Revenue ($m) by Company, 2012 124
Figure 34: APAC Revenue Growth by Company, 2012 126
Figure 35: Emerging Markets Landscape Assessment, 2012 128
Figure 36: Emerging Markets Revenue ($m) by Company, 2012 139
Figure 37: Emerging Markets Revenue Growth by Company, 2012 141
Figure 38: Headcount Growth by Company, 2012 153
Figure 39: Revenue per Employee (In $ Thousands) by Company, 2012 155
Figure 40: Clinical Srvcs Revenue per Clinical Srvcs Employee (In $ Thousands) by Company, 2012 156
Figure 41: G&A Expense per G&A Employee (In $ Thousands) by Company, 2012 157
Figure 42: S&M Expense per S&M Employee (In $ Thousands) by Company, 2012 158
Figure 43: Debt-to-Equity Ratio by Company, 4Q12 162
Figure 44: Current Ratio by Company, 4Q12 163
Figure 45: Cash Ratio by Company, 4Q12 164
Figure 46: CRO Benchmark Peer Group, Global Market Forecast, ($bn), 2012–2017 166
Figure 47: CRO Benchmark Vendor Position and 2013 Growth Projections 168

Read the full report:

PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/pharmaleaders_cro_benchmark_report_financial_performance_benchmarking_competitive_landscape_assessment_leading_cros.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com


Contact

  • Sarah Smith
    Research Advisor at Reportbuyer.com
    +44 208 816 85 48
    Email